CDK4/6i enhances the antitumor effect of PD1 antibody by promoting TLS formation in ovarian cancer

Wangyou Feng,Dongbo Jiang,Ying Xu,Yuanfeng Li,Lin Chen,Minye Zhao,Yujie Shen,Wenjing Liao,Hong Yang,Jia Li
DOI: https://doi.org/10.1016/j.heliyon.2023.e19760
IF: 3.776
2023-01-01
Heliyon
Abstract:Ovarian cancer is insensitive to immunotherapy and has a high mortality rate. CDK4/6 inhibitors (CDK4/6i) regulate the tumor microenvironment and play an antitumor role. Our previous research demonstrated that lymphocyte aggregation (tertiary lymphoid structures, TLSs) was observed after CDK4/6i treatment. This may explain the synergistic action of CDK4/6i with the anti-PD1 antibody. However, the key mechanism by which CDK4/6i promotes TLS formation has not been elucidated. We examine the link between TLS and prognosis. Animal models and highthroughput sequencing were used to explore the potential mechanism by which CDK4/6i promotes TLS formation. Our results showed the presence of TLSs was associated with a favorable prognosis for ovarian cancer. CDK4/6i promoted TLS formation and enhanced the immunotherapeutic effect of the anti-PD1 antibody. The potential mechanism of CDK4/6i affecting the formation of TLS may be through modulating SCD1 and its regulatory molecules ATF3 and CCL4. Our findings provide a theoretical basis for the application of CDK4/6i in ovarian cancer.
What problem does this paper attempt to address?